The Association of Hepatitis B Vaccine Supply Policy with Timing of Receipt of the First Dose of Hepatitis B Vaccination

Zhen Zhao, Trudy V. Murphy

National Center for HIV/AIDS, Viral Hepatitis, STD&TB prevention, Centers for Disease Control and Prevention, Atlanta, USA.
National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, USA.

DOI: 10.4236/ojs.2012.24053                

Abstract

An estimated 800,000 - 1.4 million persons in the US have chronic hepatitis B virus (HBV) infection. The risk for chronic infection is greatest among young children; approximately 90% of infants will remain chronically infected with HBV. Approximately 25% of those who become chronically infected during childhood die prematurely from cirrhosis or liver cancer. Hepatitis B vaccination is the most effective measure to prevent HBV infection and its consequences. In 2006, 29 US states had Hepatitis B Vaccine Supply (HBVS) policy which either supplies hepatitis B vaccine at no cost to all providers for all children or provides hepatitis B vaccine to delivery hospitals-only free of charge for all infants; other 21 US states and the District of Columbia did not have. 17,636 infants born in 2006 obtained from 2007-2009 National Immunization Survey (NIS) were analyzed with survival analysis procedures of Kaplan-Meier estimate and Cox proportional hazards model for complex sample survey to evaluate the association between state HBVS policy and the timing of infant age in days to receipt of hepatitis B vaccination. State HBVS policy is associated with infant age in days from birth to receipt of the first dose of hepatitis B vaccine (P < 0.01), and to completion of the 3-dose hepatitis B vaccine series (P < 0.01). Receipt of the first dose of hepatitis B vaccine occurred 31% earlier among infants residing in states with HBVS policy than among infants residing in states without (adjusted hazards ratio 1.31, 95%CI (1.23, 1.39)). Completion of the 3-dose hepatitis B vaccine series were 12% sooner among infants living in states with HBVS policy than among infants living in states without (adjusted hazards ratio 1.12, 95%CI (1.06, 1.18)). State HBVS policy may help overcome barriers to timely delivery of hepatitis B vaccines to infants.

Keywords

First Dose Hepatitis B Vaccine; 3-Dose Hepatitis B Vaccine Series; Vaccine Supply Policy; Vaccination Coverage; Cox Proportional Hazards Model

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Centers for Disease Control and Prevention, “Hepatitis B FAQs for Health Professional,” 2012. http://www.cdc.gov/hepatitis/hbv/HBVfaq.htm.
[2]	Centers for Disease Control and Prevention, “A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part 1: Immunization of Infants, Children, and Adolescents,” Morbidity and Mortality Weekly Report, Vol. 54, No. RR-16, 2005, pp. 1-23.
[3]	Centers for Disease Control and Prevention, “Hepatitis B virus: A Comprehensive Strategy for Eliminating Transmission in the United States through Universal Childhood Vaccination: Recommendations of the Immunization Practices Advisory Committee (ACIP),” Morbidity and Mortality Weekly Report, Vol. 40, No. RR-13, 1991, pp. 1-19.
[4]	American Academy of Pediatrics Committee on Infectious Diseases, “Universal Hepatitis B Immunization,” Pediatrics, Vol. 89, No. 4, 1992, pp. 795-800.
[5]	Centers for Disease Control and Prevention, “Recommended Immunization Schedule for Persons Aged 0 through 6 years—United States,” 2012. http://www.cdc.gov/vaccines/recs/schedules/downloads/c hild/0-6yrs-schedule-pr.pdf
[6]	G. M. Lee, J. M. Santoli, C. Hannan, M. L. Messonnier, J. E. Sabin, D. Rusinak, et al., “Gaps in Vaccine Financing for Underinsured Children in the United States,” Journal of the American Medical Association, Vol. 298, No. 6, 2007, pp. 638-643. doi:10.1001/jama.298.6.638
[7]	S. Stokley, K. M. Shaw, L. E. Barker, J. M. Santoli and A. Shefer, “Impact of State Vaccine Financing Policy on Uptake of Heptavalent Pneumococcal Conjugate Vaccine,” American Journal of Public Health, Vol. 96, No. 7, 2006, pp. 1308-1313. doi:10.2105/AJPH.2004.057810
[8]	L. Jacques-Carroll, S. Wang, Z. Zhao, T. Malik and F. David, “Hepatitis B Vaccination Coverage in Newborns and Vaccine Supply,” Archives of Pediatrics & Adolescent Medicine, Vol. 163, No. 5, 2009, p. 489. doi:10.1001/archpediatrics.2009.22
[9]	Centers for Disease Control and Prevention, “National and State Vaccination Coverage among Children 19-35 Months, United States 2010,” Morbidity and Mortality Weekly Report, Vol. 64, No. 34, 2011, pp. 1157-1163.
[10]	NORC at the University of Chicago, “National Immunization Survey Quarterly Report,” 2011.
[11]	E. T. Luman, A. E. Fiore, T. W. Strine and L. E. Barker, “Impact of Thimerosal-Related Changes in Hepatitis B Vaccine Birth-Dose Recommendations on Childhood Vaccination Coverage,” Journal of the American Medical Association, Vol. 291, No. 19, 2004, pp. 2351-2358. doi:10.1001/jama.291.19.2351
[12]	T. A. Santibanez, J. M. Santoli, C. B. Bridges and G. L. Euler, “Influenza Vaccination Coverage of Children Aged 6 to 23 Months: The 2002-2003 and 2003-2004 Influenza Seasons,” Pediatrics, Vol. 118, No. 3, 2006, pp. 1167- 1175. doi:10.1542/peds.2006-0831
[13]	Z. Zhao and E. T. Luman, “Progress toward Eliminating Disparities in Vaccination Coverage among US Children, 2000-2008,” American Journal of Preventive Medicine, Vol. 38, No. 2, 2010, pp. 127-137. doi:10.1016/j.amepre.2009.10.035
[14]	Centers for Disease Control and Prevention, “The National Center for Immunization and Respiratory Diseases, Annual Progress Report, VFC Program Management Survey”. http://www.cdc.gov/vaccines/programs/vfc.
[15]	Research Triangle Institute, “SUDAAN Language Manual, Release 10.0.1., Research Triangle Park, NC,” 2008.
[16]	D. S. Lauderdale, R. J. Oram, K. P. Goldstein and R. S. Daum, “Hepatitis B Vaccination among Children in Inner-City Public Housing, 1991-1997,” Journal of the American Medical Association, Vol. 282, No. 18, 1999, pp. 1725-1730. doi:10.1001/jama.282.18.1725
[17]	D. A. Binder, “Fitting Cox’s Proportional Hazards Models from Survey Data,” Biometrika, Vol. 79, No. 1, 1992, pp. 139-147. doi:10.1093/biomet/79.1.139
[18]	D. Y. Lin, “On Fitting Cox’s Proportional Models to Survey Data,” Biometrika, Vol. 87, No. 1, 2000, pp. 37-47. doi:10.1093/biomet/87.1.37
[19]	D. Hosmer and S. Lemeshow, “Applied Survival Analysis: Regression Modeling of Time to Event Data. Vol. 1,” John Wiley & Sons, New York, 1999.
[20]	G. Thabut, J. D. Christic, W. K. Kremers, M. Fourbier and S. D. Halpern, “Survival Differences Following Lung Transplantation among US Transplant Centers,” Journal of the American Medical Association, Vol. 304, No. 1, 2010, pp. 53-60.
[21]	N. M. Molinari, K. M. Wolter, B. Skalland, R. Montgomery, M. Khare, P. J. Smith, et al., “Quantifying Bias in a Health Survey: Modeling Total Survey Error in the National Immunization Survey,” Statistics in Medicine, Vol. 30, No. 5, 2011, pp. 505-514.